Search

Displaying results 1841 - 1850 of 5923 in total
  1. Drug

    Hexylresorcinol

    go.drugbank.com/drugs/DB11254
    Approved

    Hexylresorcinol is a substituted dihydroxybenzene. It exhibits antiseptic, anthelmintic, and local anesthetic properties. It can be found in topical applications for minor skin infections and in oral solutions or throat lozenges for pain...

  2. Drug

    Prezatide copper

    go.drugbank.com/drugs/DB14683
    Investigational

    Prezatide is a tripeptide consisting of glycine, histidine, and lysine which readily forms a complex with copper ions . Prezatide is used in cosmetic products for the skin and hair. It is known to aid wound healing and its potential appl...

  3. Drug

    Methadyl acetate

    go.drugbank.com/drugs/DB01433
    ExperimentalIllicit

    A narcotic analgesic with a long onset and duration of action. It is used mainly in the treatment of narcotic dependence.

  4. Drug

    Gadobutrol

    go.drugbank.com/drugs/DB06703
    ApprovedInvestigational

    Due to its physicochemical properties, gadobutrol is formulated at twice the gadolinium ion concentration compared to other GBCA and thus requires a lesser injection volume. … [A7001] Like other GBCA, gadobutrol usage carries the risk of nephrogenic systemic fibrosis (NSF) due to the dissociation of gadolinium from the chelates, although gadobutrol tends to have a lower risk

  5. Drug

    L-Acetylleucine

    go.drugbank.com/drugs/DB16956
    ApprovedInvestigational

    DL-) form has been available in France since 1957 for the treatment of vertigo. … [A264439] Observational studies in patients with Niemann-Pick disease type C (NPC) suggested a beneficial symptomatic as well as neuroprotective disease-modifying effect of the DL-form of N-acetylleucine

    Categories: P-glycoprotein inhibitors
  6. Drug

    Entrectinib

    go.drugbank.com/drugs/DB11986
    ApprovedInvestigational

    [L8207] Entrectinib's approved use is meant as a last line of therapy due to its accelerated approval based on early trial data. … This therapy offers benefit over similar ALK inhibitors such as [alectinib], [ceritinib], and [lorlatinib] due to a wider range of targets.[A183929]

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates
  7. Drug

    Spesolimab

    go.drugbank.com/drugs/DB15626
    ApprovedInvestigational

    Spesolimab is an interleukin-36 (IL-36) receptor antagonist. It is a humanized monoclonal immunoglobulin G1 antibody that was produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology. The biosimilar of the drug, spesol...

  8. Drug

    Berotralstat

    go.drugbank.com/drugs/DB15982
    ApprovedInvestigational

    Berotralstat is a selective inhibitor of plasma kallikrein used in the prophylaxis of attacks of hereditary angioedema (HAE). It works by blocking the enzymatic activity of plasma kallikrein in releasing bradykinin, the major biologic pe...

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  9. Drug

    Phosphorus

    go.drugbank.com/drugs/DB14151
    Approved

    Mixtures: Risacal-D, Brandycal-D
  10. Drug

    Ospemifene

    go.drugbank.com/drugs/DB04938
    Approved

    Ospemifene is a new selective non-hormonal estrogen receptor modulator (SERM) that is used for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 SubstratesSynonyms: 2-(p-((Z)-4-Chloro-1,2-diphenyl-1-butenyl)phenoxy)ethanol